Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Global X NASDAQ 100 Covered Call ETF trades at $18.41. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | QYLD | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $339.75 | $18.52 |
52-Week Low | $241.71 | $16.46 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
QYLD trades at $18.15, down 1.68% on the day, with technical indicators showing a neutral overall signal. The ETF's covered call strategy generates high monthly distributions but has historically lagged the Nasdaq-100's total return, with recent news highlighting NAV erosion despite consistent dividend payouts. Moving averages suggest a bullish trend while oscillators remain neutral, with all key support and resistance levels clustered around $18.
The outlook remains cautious as QYLD's high yield comes at the cost of capital appreciation potential. While attractive for income-focused investors, the strategy underperforms in strong bull markets. Key risks include capped upside and competitive pressure from lower-fee alternatives like GPIQ, requiring investors to prioritize income generation over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
